1233852-83-9

Basic information

• Product Name: N-cyclohexyl-N-methyl-4-phenyl-1H-imidazole-1-carboxamide
• CAS NO: 1233852-83-9
• Molecular Weight: 283.373
• Mol File: 1233852-83-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-cyclohexyl-N-methyl-4-phenyl-1H-imidazole-1-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-cyclohexyl-N-methyl-4-phenyl-1H-imidazole-1-carboxamide(1233852-83-9)
• EPA Substance Registry System: N-cyclohexyl-N-methyl-4-phenyl-1H-imidazole-1-carboxamide(1233852-83-9)

Safety Data

• Hazardous Substances Data: 1233852-83-9(Hazardous Substances Data)

Upstream product

• 670-95-1 4-Phenylimidazole 
• 35028-38-7 N-methyl-N-cyclohexylaminocarbonyl chloride 

Relevant articles and documents

Discovery of a Potent, Long-Acting, and CNS-Active Inhibitor (BIA 10-2474) of Fatty Acid Amide Hydrolase

Fatty acid amide hydrolase (FAAH) can be targeted for the treatment of pain associated with various medical conditions. Herein we report the design and synthesis of a novel series of heterocyclic-N-carboxamide FAAH inhibitors that have a good alignment of potency, metabolic stability and selectivity for FAAH over monoacylglycerol lipase (MAGL) and carboxylesterases (CEs). Lead optimization efforts carried out with benzotriazolyl- and imidazolyl-N-carboxamide series led to the discovery of clinical candidate 8 l (3-(1-(cyclohexyl(methyl)carbamoyl)-1H-imidazol-4-yl)pyridine 1-oxide; BIA 10-2474) as a potent and long-acting inhibitor of FAAH. However, during a Phase I clinical trial with compound 8 l, unexpected and unpredictable serious neurological adverse events occurred, affecting five healthy volunteers, including the death of one subject.

PHARMACEUTICAL COMPOUNDS

The invention relates to compounds and compositions for inhibiting the enzyme fatty acid amide hydrolase (FAAH), the use of the compounds in therapy and, in particular, for treating or preventing conditions whose development or symptoms are linked to subs